We are experienced in bringing multiple new respiratory treatments to the US and other markets.
Christophe Demaison, PhD
CEO
Christophe Demaison, PhD
CEO
Christophe has served as CEO of ENA Respiratory since the company was formed in 2020 as a spin-off from ENA Therapeutics Pty Ltd, now renamed Axelia Oncology Pty Ltd.
Passionate about building ventures and leading teams committed to translating life sciences innovations into treatments that have a meaningful impact on patients, Christophe has more than 20 years of experience spanning start-up creation, capital raising, company management, pharmaceutical product development, business development and licensing of early-stage innovations.
Christophe has a strong research and technical background. He completed his PhD in immunology at the Pasteur Institute, Paris, France before moving to Great Ormond Street Hospital, London, UK where his research led in 2002 to Britain’s first successful gene therapy clinical trial for the treatment of immune deficiencies in children.
Kevin Fischer
Chief Financial Officer
Kevin Fischer
Chief Financial Officer
Kevin is a seasoned finance professional with more than 20 years’ experience in strategic financial management, operational leadership, risk oversight, and corporate governance.
He has held senior finance roles across both private and public sectors, including prominent positions at Wavewise Analytics Pty Ltd, Gallagher eShepherd Pty Ltd, QIAGEN, Cellestis Limited, and Genetic Technologies Limited, partnering closely with boards and executive teams to deliver robust outcomes.
Kevin is a Fellow Member of CPA Australia (FCPA) and the Governance Institute of Australia (FGIA), and holds a Bachelor of Commerce degree from the University of Natal in South Africa.
Ruth Tal-Singer, PhD
Medicine Development Leader
Ruth Tal-Singer, PhD
Medicine Development Leader
Ruth joined ENA as a strategy consultant in 2020, and since April 2023 has served as Medicine Development Leader. Previously she was President and CEO of the US COPD Foundation, where she championed a strategic partnership and served as a member of ENA’s Board of Directors until March 2023.
Ruth is an internationally recognised innovative, patient-focused and highly analytical healthcare leader and clinical scientist with extensive pharmaceutical Research and Development experience. She was previously VP, Medical Innovation at GSK, focusing on enhancing the value of GSK’s Respiratory portfolio. She was also a Member of the Respiratory Therapy Area Unit Executive Team at GSK.
She has a proven history of successfully leading international public and private partnerships and non-profit organizations through critical advancements and progress in clinical trials and large observational cohorts. Since retiring from GSK in 2019, she has worked as an independent consultant and volunteers as chief scientific officer of the not-for-profit Global Allergy and Airways Patient Platform (GAAPP).
Ruth received a PhD in Molecular Biology, Microbiology from the University of Pennsylvania. She has authored 200+ peer-reviewed manuscripts including highly cited scientific publications.
Courtney Crim, MD
Chief Medical Officer
Courtney Crim, MD
Chief Medical Officer
Courtney joined ENA Respiratory in 2023 as its consultant Chief Medical Officer. He is also a Clinical Associate Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the University of North Carolina.
Courtney previously served as Group Director in Respiratory Clinical Development at GSK. He has approximately 22 years of experience designing Phase II-IV clinical trials, and has presented submissions for drug approval at US, European and other country regulatory agencies.
Courtney is certified by the American Board of Internal Medicine in Internal Medicine, Pulmonary Diseases and Critical Care Medicine. He has authored or co-authored over 100 peer-reviewed published manuscripts.
He is a Fellow of the American College of Chest Physicians and the American Thoracic Society and, as to the latter, is the immediate past-chair of the Drug/Device Discovery and Development Committee of the American Thoracic Society.
Courtney received a Doctor of Medicine, MD from the University of Michigan Medical School.
Grant Mclachlan, PhD
Director, CMC Program Management
Grant Mclachlan, PhD
Director, CMC Program Management
Grant joined ENA Respiratory in 2020, overseeing the company’s CMC activities.
He brings over 25 years of experience in drug development, including managing CMC activities.
Previously, Grant was CEO at Armaron Bio and led the company through fund raising, and pre-clinical development to the completion of a Phase II clinical trial.
Earlier roles in his career, included a Project Manager at Melbourne Ventures, where he was responsible for a number of the University of Melbourne’s research translation and commercialisation opportunities, and working at IDT Australia, where he focused on API process development and scale-up for clinical trial and commercial supply.
Grant completed his post-doctoral research in the USA.
He has a PhD in Chemistry from Monash University, Australia.
Francesca Mercuri, PhD
Director of Biology
Francesca Mercuri, PhD
Director of Biology
Francesca joined ENA Respiratory in 2020, overseeing the translational research and clinical operation programs. She has over 20 years of experience in the successful management of pre-clinical research programs and multi-institutional partnerships between academic institutions and industry.
Earlier, during her postdoctoral research, Francesca was awarded a Wellcome Trust Fellowship from the University of East Anglia, UK and a NH&MRC Postdoctoral Fellowship.
Francesca received her PhD in molecular biology from the University of Melbourne and her B.S, Honours in Immunology from Monash University, Australia.
Becky Smith
Project & Portfolio Management Lead
Becky Smith
Project & Portfolio Management Lead
Becky has more than 25 years’ experience in pharmaceutical and biotechnology R&D, managing projects and portfolios from preclinical evaluation through clinical development, regulatory submission, launch and lifecycle management. She has held senior leadership roles at GSK and Galecto, where she provided strategic project and portfolio management across complex global development programmes.
As an independent consultant, Becky supports life sciences companies with project management, portfolio leadership and operational strategy. She works with leadership teams to translate strategy into clear priorities, effective plans and successful execution. Her therapeutic area experience spans respiratory, immuno-inflammation, oncology and liver disease.
Bruce Miller, PhD
Clinical Science Lead
Bruce Miller, PhD
Clinical Science Lead
Bruce has 30 years’ experience in drug development and led multiple drug development programs in COPD and other inflammatory diseases having held senior scientific roles with GSK, Johnson & Johnson, Rhone-Poulenc Rorer, and Sterling-Winthrop Pharmaceuticals.
Bruce was a key participant in numerous public-private collaborations that furthered disease understanding in COPD. He was co-chair for the COPD Foundation’s Biomarker Qualification Consortium’s Fibrinogen Working Group, producing work that resulted in the first regulatory qualification with FDA and EMA for a biomarker to support COPD clinical trials.
Bruce is now a consultant to industry and other organisations providing expert input into drug development programs and disease understanding efforts. He has authored/co-authored over 200 peer-reviewed publications in respiratory research and inflammation/immunology and is a co-inventor on three issued international patents.
Bruce received his Ph.D. from in Toxicology and Pharmacology from The University of North Carolina at Chapel Hill.
Courtney Nelson-Douthit
Clinical Operations Lead, US
Courtney Nelson-Douthit
Clinical Operations Lead, US
Courtney has served as a Clinical Operations Consultant to ENA Respiratory since 2025. She has more than 14 years of operational experience spanning project management, data management and clinical operations oversight for large multi-center trials in neuroscience, cell and gene therapy, and medical devices.
As an Associate Director, Global Project Delivery within The Emmes Group, she serves as a subject matter expert for biotech clients leveraging her expertise in clinical trial implementation and execution, from protocol development through the clinical study report (CSR), including vendor selection, EDC design, DSMB/DMC Support, and regulatory inspection preparation.
Courtney has a B.S. in Engineering Science and a B.A. in Physics from the University of Virginia. Through her work in the Neuroscience and Hematology/Oncology space, she has co-authored peer-reviewed publications in the Journal of Clinical Oncology (2019) and JAMA (2023) and has delivered oral and poster presentations at national and international scientific meetings.
Michelle Di Vito-Smith
Clinical Operations Lead, AUS
Michelle Di Vito-Smith
Clinical Operations Lead, AUS
Michelle is an accomplished clinical operations professional who partners with biopharmaceutical companies to translate innovative therapies into well-executed clinical trials. Following extensive experience across the biopharmaceutical and contract research sectors, she established her own consultancy in 2020 to provide tailored clinical operations expertise and hands-on support to sponsors throughout the clinical development journey.
She holds a First-Class Honours degree in Pharmacology and brings broad experience spanning Clinical Operations and Field Medical Affairs. With a strong focus on collaboration, strategic partnership and operational excellence, Michelle works closely with biotech sponsors, investigators and clinical research sites to navigate the complexities of clinical trial delivery. Her expertise spans clinical trial planning, start-up, site engagement and trial execution, with a commitment to delivering efficient, high-quality and compliant outcomes. She is recognised for building trusted relationships, providing practical solutions and aligning operational strategies with sponsor priorities to help bring new therapies closer to patients.
Beyond her work, Michelle is passionate about advancing clinical research through greater public awareness, education and community engagement. Driven by a commitment to improving understanding of clinical trials and upper gastrointestinal cancers, she is a member of the Clinical Advisory Committee for PanCare.
Patrick Wire, PharmD
Regulatory Strategy Leader
Patrick Wire
Regulatory Strategy Leader
Patrick Wire, PharmD., is an independent regulatory affairs consultant with over 25 years of experience in pharmaceutical development, specializing in respiratory medicines.
Prior to working as an independent consultant, Patrick held senior leadership positions at GlaxoSmithKline, including Senior Director of Global Regulatory affairs, where he led regulatory strategies for multiple respiratory products. Throughout his career, Patrick has played a key role in numerous successful regulatory submissions and product approvals, including Breo, Anoro, Incruse, and Arnuity.
He has extensive experience in global regulatory strategy, clinical development, FDA interactions, and advisory committee preparations. Drawing on his background in clinical pharmacology, clinical research, and regulatory affairs, Patrick now provides strategic regulatory guidance to pharmaceutical companies developing innovative therapies.
Narani Smyth
Senior Quality Assurance & CMC Project Manager
Narani Smyth
Senior Quality Assurance & CMC Project Manager
Narani joined ENA Respiratory in 2024, in a senior project management role. She has over 20 years of experience in pharmaceuticals, including Quality Assurance and Manufacturing.
Narani has worked in various roles at Pfizer, IDT, Peter MacCallum Cancer Centre and Cell Therapies.
She played a key role in the Novartis technology transfer of Kymriah, a CAR T cell therapy, and was the overall Quality Assurance with responsibility for the commercial delivery of batches for Australia.
Narani has a BSc in Pharmacology from The University of Melbourne, Australia.















